Designee builds on commitment to furthering excellence in the healthcare sector’s information security and privacy programs

Apgar & Associates logo
infosec and privacy consultants Apgar & Associates logo, HITRUST designee

PORTLAND, Ore. – October 12, 2022 – (Newswire.com)

Apgar & Associates, LLC today announced that it is designated as a HITRUST Readiness Licensee. With this achievement, Apgar & Associates is approved by HITRUST to perform consulting and readiness work for organizations looking to adopt the HITRUST CSF or prepare for their first assessment. For over a decade, the consultancy has provided information security and privacy services that encompass strategic planning for risk management and compliance programs, as well as consulting on security incidence response, risk analysis, and policy and procedures. 

HITRUST Readiness Licensees help uphold information security and privacy standards for various industries of varying size and complexity by assisting clients with the adoption of the HITRUST CSF framework, implementation, and remediation efforts following adoption, and facilitated self-assessments.

“We’re very pleased to receive the HITRUST Readiness designation. It feels like a natural progression in our firm’s commitment to furthering excellence in the healthcare sector’s information security and privacy programs,” stated Julia Huddleston, CIPP/US, CIPM, CCSFP, and Principal Consultant at Apgar & Associates, LLC. “We look forward to helping guide healthcare providers and their business associates through the what and how of readying for the HITRUST assessment.”

“Readiness Licensees meet the criteria to become trusted and independent resources for clients needing to improve their security posture,” said Matthew Datel, Director, Education & Strategic Initiatives at HITRUST. “Readiness Licensees are helpful in providing qualified third-party reviews for clients preparing for or seeking HITRUST CSF Certification.”

About Apgar & Associates

The consultancy’s information security and privacy services encompass strategic planning for risk management and compliance programs, as well as consulting on security incidence response, risk analysis, and policy and procedures.

The team also helps organizations decide which of the various industry certifications aligns best with the business’ privacy and information security strategy. For more information about Apgar & Associates’ consulting services, such as HITRUST Readiness, please contact the company at 503-384-2538 or visit its website at https://apgarandassoc.com/.

Contact Information:

Nora Haile

Marketing Consultant

nora@nhaile.com

520-425-6498

Press Release Service
by
Newswire.com

Original Source:

Apgar & Associates Achieves HITRUST® Readiness Licensee Designation

The agreement brings together two industry leaders, leveraging complementary strengths to enhance support of doctors in building successful dental practices. This new education platform is called Group Dentistry Instit…

Miami Beach walking tour down Ocean Drive during Spring Break. We walk around and compare 2021 spring break and 2022 spring break. Things seem much more controlled and movement within south beach seems more normal. Miami Beach Police were making sure all visitors were safe and having a great time. My name is Alfred Montaner […]

The post Spring Break Miami Beach 2022 ! (Ocean Drive Walking Tour ) first appeared on Miami In News.

Detectives seized millions of dollars of drugs along with guns and cash and arrested 85 suspects accused in an international drug smuggling operation. FOX 13 Tampa Bay brings you the important videos like breaking news, Tampa Bay weather, and local stories. But also plenty of fun stuff, like ‘We Live Here’ tips, the best of […]

THE NEW STUDIO ALBUM “NOBODY’S FOOL” WILL RELEASE OCTOBER 28th BY KTBA RECORDS AVAILABLE ON CD, VINYL AND DIGITAL BOCA RATON, FL, UNITED STATES, September 28, 2022 /EINPresswire.com/ — Today, Joanne Shaw Taylor releases “Fade Away,” the next breathtaking single taken from her forthcoming breakthrough studio album Nobody’s Fool. The single can be streamed here. […]

New line of mushroom-powered gummies targets creating quick natural health benefits in the daily routine.

Troomy Mushroom Gummies
…

In 2022 Mazda remains as elegant as ever and keeps the fabled Japanese reliability. Today we will cover their latest car lineup that now includes some worthy crossover SUVs. Join us on this informative journey with #AutomotiveTerritoryDailyNews. #1 2023 Mazda CX-60 2023 Mazda CX-60 is the first plug-in hybrid SUV from the brand that belongs […]

Dr. Korb Dr. Korb with her dogs, Charlie and Tucker
CHARLESTON, S.C. – October 11, 2022 – (Newswire.com)
…

Ambit to showcase its prevalence projection approach, co-developed with Praxis, for rare developmental and epileptic encephalopathies (DEEs) as a Platform Presentation at this year’s annual Child Neurology Society meeting

CINCINNATI – October 11, 2022 – (Newswire.com)

Ambit^®, a data and technology-enabled biopharma services company, today announced that leadership will debut Ambit’s data-driven methodology for projecting prevalence and diagnosis rates for difficult-to-quantify DEEs at the 51^st Annual Child Neurology Society Meeting on Oct. 13, 2022. Ambit’s analytics team has developed this methodology in collaboration with Praxis Precision Medicines, Inc. (NASDAQ: PRAX) and the UCSF Weill Institute for Neurosciences and Benioff Children’s Hospitals.

For many rare DEEs, reliable prevalence estimates are not available. With a robust and growing pipeline of precision medicine therapies in rare epilepsy and neurodevelopmental disorders, estimating the prevalence of these conditions with a data-driven methodology can be highly valuable to drug developers, medical device companies and other healthcare decision-makers.

“Ambit’s expertise in a data-driven approach to prevalence projections for rare neurological conditions has allowed Praxis to characterize DEE populations with a high degree of confidence,” said Marcio Souza, president and chief executive officer of Praxis. “As we seek to bring first-in-class, potentially disease-modifying therapies to DEE patients in need, our collaboration with Ambit has been invaluable in increasing our understanding of these patient groups.”

Despite the availability of sponsored genetic testing and increased awareness of the benefit of genetic testing, over 50% of patients with rare DEEs remain undiagnosed. Sizing these patient populations and diagnosis rates underscores the importance of earlier genetic testing for unexplained seizure disorders and rare DEEs. “Even today, the path to accurate diagnosis and appropriate care for rare genetic epilepsies can be long and full of challenges,” said Adam Numis, M.D., of the UCSF Benioff Children’s Hospital. “Ambit’s methodology underscores the need for more treatment options to improve outcomes and quality of life for the rare DEE population.”

Ambit chief executive officer, Robert Sederman, will present this methodology on Oct. 13 as part of the Platform II Presentation Session (PL2-1) at the 2022 Annual Child Neurology Society Meeting. Presentations will run from 7-9 a.m. ET in the Junior Ballroom CD at the Duke Energy Center. Ambit will be presenting from 7-7:15 a.m. The associated abstract will be published in a supplement to the October issue of Annals of Neurology.

“We are excited to partner with Praxis and UCSF to showcase Ambit’s DEE projection methodology at this year’s meeting and, ultimately, see the impact of this collaboration on greater access to accurate diagnosis and treatment for patients with rare DEEs in the future,” said Sederman.
 

About Ambit Inc.

Ambit Inc.^® is a data and technology-enabled biopharma and healthcare services company with a focus on rare and specialty disease. Ambit’s patient identification services drive patient activation and earlier diagnosis for patients that may be suffering from rare diseases. Ambit’s analytics and professional services support rare and specialty biopharma across the clinical development and commercialization of potentially life-changing therapies. To learn more about Ambit’s DEE Projection approach and other capabilities, please reach out to inquiries@ambitinc.com.

About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across movement disorders, epilepsy and psychiatric disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.  

Contact Information:

Alexis Burbank

Marketing, Ambit Inc.

inquiries@ambitinc.com

Press Release Service
by
Newswire.com

Original Source:

Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting

Tuffy Tire & Auto Service recommends AutoVitals software solutions across their network of over 160 locations.

AutoVitals AutoVitals Logo
…